Company profile
Onconova Therapeutics, Inc.
NASDAQ: ONTX · Financial Services · Asset Management
#722 of 1,012 Financial Services companies by revenuetop-decile growth
EA Score
47DFH 40DQ 53GM 67SS 31
v0.1 · 65/100 weight · provisional
↑ return on assets, revenue growth (YoY) · ↓ growth stability, Piotroski F
Methodology →Revenue TTM
$2.8B
Rev growth YoY (TTM)
+1228949.9%
Net income (FY)
$9.2M
Employees
16
as of 2026-08-12
Market cap
$1.1M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.8M$2.8M2024
Net income$9.2M$9.2M2024
Operating income-$17.9M-$17.9M2024
Total assets$10.6M$10.6M2024
Liabilities$11.2M$11.2M2024
Equity-$629.0k-$629.0k2024
Revenue trend
FY2018 – FY2024 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY24
Revenue by segment
Filed disclosures · FY2018
By product
Hanx Upfront Licence Payment37%
Symbio Amortization Of Upfront Payment32%
Pint Upfront Licence Payment26%
Supplies5%
By geography
Not disclosed.
The read
What is Onconova Therapeutics, Inc.’s revenue?
Onconova Therapeutics, Inc. booked $2.8M in FY2024 revenue, growing 1135% year over year — faster than 98% of Financial Services companies we track, at a 328.7% net margin.
Peers · Financial Services
Rhinebeck Bancorp, Inc.49DPCB Bancorp59CBankwell Financial Group, Inc.60CTorrent Capital Ltd.——Reservoir Capital Corp.——Kearny Financial Corp.45DKey facts
CEOSteven Fruchtman
SectorFinancial Services
IndustryAsset Management
HeadquartersNewtown, PA
ExchangeNASDAQ: ONTX
Employees16
IPO date2013-07-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.